[go: up one dir, main page]

DK2968173T3 - Heterocykliske forbindelser og anvendelser deraf - Google Patents

Heterocykliske forbindelser og anvendelser deraf Download PDF

Info

Publication number
DK2968173T3
DK2968173T3 DK14719472.4T DK14719472T DK2968173T3 DK 2968173 T3 DK2968173 T3 DK 2968173T3 DK 14719472 T DK14719472 T DK 14719472T DK 2968173 T3 DK2968173 T3 DK 2968173T3
Authority
DK
Denmark
Prior art keywords
heterocyclic compounds
heterocyclic
compounds
Prior art date
Application number
DK14719472.4T
Other languages
English (en)
Inventor
Mingda Bi
Robert Kuehl
Original Assignee
Amgen Inc
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50549466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2968173(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc, Cytokinetics Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK2968173T3 publication Critical patent/DK2968173T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK14719472.4T 2013-03-14 2014-03-14 Heterocykliske forbindelser og anvendelser deraf DK2968173T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361785763P 2013-03-14 2013-03-14
PCT/US2014/027104 WO2014152236A1 (en) 2013-03-14 2014-03-14 Heterocyclic compounds and their uses

Publications (1)

Publication Number Publication Date
DK2968173T3 true DK2968173T3 (da) 2020-12-21

Family

ID=50549466

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14719472.4T DK2968173T3 (da) 2013-03-14 2014-03-14 Heterocykliske forbindelser og anvendelser deraf
DK14720369.9T DK2970123T3 (da) 2013-03-14 2014-03-14 Salt af omecamtiv mecarbil og fremgangsmåde til fremstilling heraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14720369.9T DK2970123T3 (da) 2013-03-14 2014-03-14 Salt af omecamtiv mecarbil og fremgangsmåde til fremstilling heraf

Country Status (42)

Country Link
US (15) US9951015B2 (da)
EP (3) EP2968173B1 (da)
JP (5) JP6783138B2 (da)
KR (2) KR102474467B1 (da)
CN (3) CN105209437B (da)
AP (1) AP2015008789A0 (da)
AR (2) AR095542A1 (da)
AU (2) AU2014240049C1 (da)
BR (2) BR112015022857B1 (da)
CA (3) CA2902646C (da)
CL (1) CL2015002708A1 (da)
CR (1) CR20150549A (da)
CY (2) CY1122695T1 (da)
DK (2) DK2968173T3 (da)
EA (1) EA031185B1 (da)
ES (2) ES2750676T3 (da)
HK (1) HK1218080A1 (da)
HR (2) HRP20201967T1 (da)
HU (2) HUE046285T2 (da)
IL (2) IL240788B (da)
JO (1) JOP20140114B1 (da)
LT (2) LT2968173T (da)
MA (2) MA44637B1 (da)
ME (1) ME03566B (da)
MX (3) MX363347B (da)
MY (2) MY204971A (da)
NZ (1) NZ711225A (da)
PE (1) PE20151786A1 (da)
PH (2) PH12019500176B1 (da)
PL (2) PL2968173T3 (da)
PT (2) PT2970123T (da)
RS (2) RS61215B1 (da)
RU (1) RU2663663C2 (da)
SA (1) SA515361088B1 (da)
SG (2) SG11201507258PA (da)
SI (2) SI2970123T1 (da)
SM (2) SMT202000685T1 (da)
TN (1) TN2015000380A1 (da)
TW (1) TWI667026B (da)
UA (1) UA117011C2 (da)
UY (1) UY35449A (da)
WO (2) WO2014152236A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA016138B1 (ru) 2004-06-17 2012-02-28 Цитокинетикс, Инк. Соединения, фармацевтические композиции и способы лечения сердечной недостаточности
WO2014152236A1 (en) 2013-03-14 2014-09-25 Amgen Inc. Heterocyclic compounds and their uses
TWI790189B (zh) 2015-01-02 2023-01-21 美商梅拉洛伊卡公司 細菌組成物
JP6858716B2 (ja) 2015-06-26 2021-04-14 アムジエン・インコーポレーテツド 心筋ミオシン活性化剤と洞房結節If電流阻害剤の併用療法
PT3645002T (pt) 2017-06-30 2025-01-24 Amgen Inc Métodos de tratamento da insuficiência cardíaca com ativadores do sarcómero cardíaco
ES2882905T3 (es) 2017-06-30 2021-12-03 Amgen Inc Síntesis de omecamtiv mecarbil
EA039850B1 (ru) * 2018-04-30 2022-03-21 Эмджен Инк. Синтез омекамтива мекарбила
DK3594199T3 (da) 2018-07-09 2020-09-14 Fis Fabbrica Italiana Sintetici Spa Krystallinsk 2-flour-3-nitrotoluen og proces til forberedelse deraf
WO2020014406A1 (en) 2018-07-12 2020-01-16 Assia Chemical Industries Ltd. Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
US11465969B2 (en) 2018-08-17 2022-10-11 Cytokinetics, Inc. Salts and crystal forms of omecamtiv mecarbil
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
EP3938042A1 (en) * 2019-03-12 2022-01-19 Amgen Inc. Polymorphs of a cardiac troponin activator
US12187700B2 (en) * 2019-03-12 2025-01-07 Amgen Inc. Polymorphs and cocrystals of a cardiac troponin activator
US20220348543A1 (en) * 2019-09-19 2022-11-03 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4031541A1 (en) 2019-09-19 2022-07-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021070123A1 (en) * 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
AU2021221106A1 (en) 2020-02-10 2022-09-22 Amgen Inc. Omecamtiv mecarbil tablet
JP2022039996A (ja) * 2020-08-26 2022-03-10 アムジエン・インコーポレーテツド Mcl-1阻害剤処方物
KR20230107282A (ko) 2020-11-12 2023-07-14 암젠 인크 오메캄티브 메카빌을 투여하여 심부전을 치료하는 방법
WO2022177927A1 (en) * 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt
JP2024509797A (ja) 2021-03-10 2024-03-05 アムジェン インコーポレイテッド オメカムチブメカルビルの合成
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2788775B1 (fr) 1999-01-22 2001-04-13 Pf Medicament Nouvelles n-alcoyl-n-[1-(omega-(arylalcoyloxy)alcoyl] piperidin-4-yl]-4h-3,1-benzo(thia/oxa)zines-2-amines substituees, leur preparation et leur application en therapeutique
GEP20043334B (en) 1999-12-23 2004-03-10 Pfizer Prod Inc Hydrogel-Driven Drug Dosage Form
GB0124455D0 (en) * 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
JP2005531492A (ja) 2001-10-17 2005-10-20 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 高リスク患者のii型糖尿病を低減させる方法
US20050096365A1 (en) 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
EA016138B1 (ru) 2004-06-17 2012-02-28 Цитокинетикс, Инк. Соединения, фармацевтические композиции и способы лечения сердечной недостаточности
WO2007054975A1 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders
TW200738243A (en) * 2005-11-15 2007-10-16 Glaxo Group Ltd Novel process and formulations
US20070208000A1 (en) 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
EP1959960B1 (en) 2005-12-15 2013-04-10 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US7989455B2 (en) * 2005-12-19 2011-08-02 Cytokinetics, Inc. Compounds, compositions and methods
US7639112B2 (en) 2007-04-25 2009-12-29 Sony Corporation Fuse device with integrated switch
US20090192168A1 (en) * 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
TW201006816A (en) * 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
EP3753565A1 (en) 2008-10-03 2020-12-23 ViCardia Therapeutics, Inc. Aica riboside analogs for treatment of cardiac and other conditions
US9253433B2 (en) 2012-11-27 2016-02-02 International Business Machines Corporation Method and apparatus for tagging media with identity of creator or scene
WO2014152236A1 (en) 2013-03-14 2014-09-25 Amgen Inc. Heterocyclic compounds and their uses
US9895308B2 (en) * 2013-03-14 2018-02-20 Amgen Inc. Heterocyclic compounds and their uses
EP3250557B1 (en) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
JP6858716B2 (ja) 2015-06-26 2021-04-14 アムジエン・インコーポレーテツド 心筋ミオシン活性化剤と洞房結節If電流阻害剤の併用療法
PT3645002T (pt) 2017-06-30 2025-01-24 Amgen Inc Métodos de tratamento da insuficiência cardíaca com ativadores do sarcómero cardíaco
ES2882905T3 (es) * 2017-06-30 2021-12-03 Amgen Inc Síntesis de omecamtiv mecarbil
DK3594199T3 (da) 2018-07-09 2020-09-14 Fis Fabbrica Italiana Sintetici Spa Krystallinsk 2-flour-3-nitrotoluen og proces til forberedelse deraf
WO2020014406A1 (en) 2018-07-12 2020-01-16 Assia Chemical Industries Ltd. Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
US11465969B2 (en) 2018-08-17 2022-10-11 Cytokinetics, Inc. Salts and crystal forms of omecamtiv mecarbil
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
US20220348543A1 (en) 2019-09-19 2022-11-03 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4031541A1 (en) 2019-09-19 2022-07-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021070123A1 (en) 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
EP4041710A1 (en) 2019-10-09 2022-08-17 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
WO2021136477A1 (zh) 2020-01-03 2021-07-08 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
AU2021221106A1 (en) 2020-02-10 2022-09-22 Amgen Inc. Omecamtiv mecarbil tablet
KR20230107282A (ko) 2020-11-12 2023-07-14 암젠 인크 오메캄티브 메카빌을 투여하여 심부전을 치료하는 방법
WO2022177927A1 (en) 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt
JP2024509797A (ja) 2021-03-10 2024-03-05 アムジェン インコーポレイテッド オメカムチブメカルビルの合成
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Also Published As

Publication number Publication date
KR20150136063A (ko) 2015-12-04
US20180312469A1 (en) 2018-11-01
MX2015012414A (es) 2016-04-25
IL240788B (en) 2020-09-30
RU2015143643A (ru) 2017-04-18
LT2968173T (lt) 2021-03-25
PH12019500176B1 (en) 2023-08-11
JP7174132B2 (ja) 2022-11-17
CA2902646C (en) 2022-08-16
HK1219484A1 (zh) 2017-04-07
PL2970123T3 (pl) 2020-03-31
CR20150549A (es) 2016-01-04
US20200331859A1 (en) 2020-10-22
EP2970123A1 (en) 2016-01-20
JP2019059746A (ja) 2019-04-18
JP2016513683A (ja) 2016-05-16
HRP20201967T1 (hr) 2021-03-05
UA117011C2 (uk) 2018-06-11
US9988354B2 (en) 2018-06-05
HUE052355T2 (hu) 2021-04-28
MA38399B2 (fr) 2020-12-31
CY1122695T1 (el) 2021-03-12
PH12015501998A1 (en) 2016-01-11
CA2902436A1 (en) 2014-09-25
SG10201706656RA (en) 2017-09-28
JP6966590B2 (ja) 2021-11-17
HK1218544A1 (en) 2017-02-24
IL241089B (en) 2019-10-31
PH12015501998B1 (en) 2016-01-11
SMT201900563T1 (it) 2019-11-13
US20140309235A1 (en) 2014-10-16
US10421726B2 (en) 2019-09-24
CL2015002708A1 (es) 2016-03-11
AR129504A2 (es) 2024-09-04
EA201591728A1 (ru) 2016-01-29
JP6783138B2 (ja) 2020-11-11
US11958809B2 (en) 2024-04-16
US9951015B2 (en) 2018-04-24
CA3147180A1 (en) 2014-09-25
SA515361088B1 (ar) 2018-07-22
DK2970123T3 (da) 2019-10-21
SI2970123T1 (sl) 2019-12-31
SG11201507258PA (en) 2015-10-29
BR112015022857B1 (pt) 2022-10-25
US12275704B2 (en) 2025-04-15
US20200079736A1 (en) 2020-03-12
RS59536B1 (sr) 2019-12-31
US20240217933A1 (en) 2024-07-04
HUE046285T2 (hu) 2020-02-28
MA38399A1 (fr) 2017-01-31
EP2968173A1 (en) 2016-01-20
TW201524507A (zh) 2015-07-01
JP6689942B2 (ja) 2020-04-28
US20230044617A1 (en) 2023-02-09
CN108785265A (zh) 2018-11-13
KR102374159B1 (ko) 2022-03-15
JP6498658B2 (ja) 2019-04-10
EP3821882A1 (en) 2021-05-19
CN105209437B (zh) 2018-09-18
AU2014240049C1 (en) 2019-03-07
AU2014240049A1 (en) 2015-09-10
NZ750950A (en) 2020-09-25
CY1123633T1 (el) 2022-03-24
ES2837038T3 (es) 2021-06-29
CA2902646A1 (en) 2014-09-25
TWI667026B (zh) 2019-08-01
BR112015023417A2 (pt) 2017-07-18
PH12019500176A1 (en) 2020-11-04
US11884630B2 (en) 2024-01-30
HK1218512A1 (zh) 2017-02-24
PL2968173T3 (pl) 2021-03-08
US20180273479A1 (en) 2018-09-27
HK1218080A1 (zh) 2017-02-03
BR112015023417B1 (pt) 2023-10-17
JP2020125307A (ja) 2020-08-20
IL241089A0 (en) 2015-11-30
MA44637B1 (fr) 2021-04-30
MX363347B (es) 2019-03-20
IL240788A0 (en) 2015-10-29
US20240101517A1 (en) 2024-03-28
MX2015012429A (es) 2016-04-07
AU2014239995B2 (en) 2018-07-26
PT2968173T (pt) 2020-12-18
LT2970123T (lt) 2019-11-11
AU2014240049B2 (en) 2018-07-19
US20200277261A1 (en) 2020-09-03
UY35449A (es) 2014-09-30
EA031185B1 (ru) 2018-11-30
RU2663663C2 (ru) 2018-08-08
CN108785265B (zh) 2024-10-08
BR112015022857A2 (pt) 2017-07-18
US20220153700A1 (en) 2022-05-19
ME03566B (me) 2020-07-20
EP2968173B1 (en) 2020-10-14
AU2014239995A1 (en) 2015-09-10
US11472773B2 (en) 2022-10-18
CN105120844A (zh) 2015-12-02
MY204971A (en) 2024-09-25
PT2970123T (pt) 2019-10-28
KR102474467B1 (ko) 2022-12-05
AP2015008789A0 (en) 2015-10-31
US20200399221A1 (en) 2020-12-24
JP2022023891A (ja) 2022-02-08
TN2015000380A1 (en) 2017-01-03
CA3147180C (en) 2024-04-23
JOP20140114B1 (ar) 2021-08-17
SI2968173T1 (sl) 2021-04-30
US20220298114A1 (en) 2022-09-22
US20160016906A1 (en) 2016-01-21
NZ711225A (en) 2020-06-26
CN105209437A (zh) 2015-12-30
ES2750676T3 (es) 2020-03-26
MY186048A (en) 2021-06-17
WO2014152236A1 (en) 2014-09-25
AR095542A1 (es) 2015-10-21
JP2016519071A (ja) 2016-06-30
EP2970123B1 (en) 2019-08-14
MA44637A1 (fr) 2019-08-30
WO2014152270A1 (en) 2014-09-25
PE20151786A1 (es) 2015-12-11
US12221417B2 (en) 2025-02-11
KR20220045014A (ko) 2022-04-12
HRP20191728T1 (hr) 2019-12-13
MX2021001231A (es) 2021-04-12
US20250243163A1 (en) 2025-07-31
US11384053B2 (en) 2022-07-12
US20240317687A1 (en) 2024-09-26
SMT202000685T1 (it) 2021-01-05
RS61215B1 (sr) 2021-01-29

Similar Documents

Publication Publication Date Title
DK3052485T3 (da) Heterocykliske forbindelser og anvendelser deraf
DK2968173T3 (da) Heterocykliske forbindelser og anvendelser deraf
HRP20181392T1 (hr) Heterociklični spojevi i njihova uporaba
DK3043784T3 (da) Arylethere og anvendelser deraf
DK3381917T3 (da) Imidazopyridinforbindelser og anvendelser deraf
IL243420A0 (en) Heterocyclic compounds and their uses
DK3003039T3 (da) Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
DK3016946T3 (da) Substituerede benzofuranyl- og benzoxazolylforbindelser og anvendelser deraf
DK3063144T3 (da) Antiparasitære og pesticid-isoxazolinforbindelser
DK3089994T3 (da) Fabs-in-tandem-immunglobulin og anvendelser deraf
DK2968443T3 (da) Hepcidinanaloger og anvendelser deraf
DK2962100T3 (da) Tuberkulosebiomarkører og anvendelser deraf
DK3030549T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
PL3030519T3 (pl) Trójpierścieniowe związki benzoksaborolu i ich zastosowania
DK3029038T3 (da) Tetrazolinonforbindelse og anvendelse deraf
DK2986618T3 (da) Organiske anion-lithium-ion-co-krystalforbindelser og sammensætninger
DK3066089T3 (da) Substituerede n-acetyl-l-cysteinderivater og relaterede forbindelser
HRP20190133T1 (hr) Heterociklički spoj
DK3077510T3 (da) Antisense-forbindelser og anvendelser deraf
DK3012259T3 (da) Fem-leddede heterocykliske pyridinforbindelser og fremstillingsfremgangsmåde og anvendelse deraf
TH1501003198A (th) สารประกอบเฮเทอโรไซคลิค